Curis Reaffirms Initial Patient Dosing Timeline for TakeAim CLL Trial
LEXINGTON, Mass., June 26, 2026 Curis, Inc. announced continued progress in its Phase 2 TakeAim CLL clinical trial, confirming...
Chronic Lymphocytic Leukemia
Advertisement
Everest Medicines Eyes China Approval for LEROCHOL® PCSK9 Therapy
SHANGHAI, China, June 26, 2026 Everest Medicines announced a significant regulatory milestone after China’s National Medical Products Administration (NMPA)...
Lilly Jaypirca CHMP Backs EU Approval for CLL Treatment
INDIANAPOLIS, June 26, 2026 Eli Lilly and Company announced that the European Medicines Agency’s Committee for Medicinal Products for...
Lilly’s Jaypirca Reduces Risk of Disease Progression or Death by 45% in CLL/SLL
INDIANAPOLIS, Indiana, June 14, 2026 Eli Lilly and Company announced compelling results from the pivotal Phase 3 BRUIN CLL-322...
AbbVie Reports 9-Year VENCLEXTA Data in First-Line CLL
NORTH CHICAGO, Ill., June 12, 2026 AbbVie announced new long-term clinical results from the Phase 3 CLL14 trial at...
Advertisements
Roche Partners with Nurix to Advance BTK Degrader Bexobrutideg Across Cancer, Immunology and Neurology
BASEL, Switzerland, June 8, 2026 Roche announced a global licensing and collaboration agreement with Nurix Therapeutics to co-develop and...
AbbVie Secures EU Approval for Expanded VENCLYXTO Use in First-Line CLL
NORTH CHICAGO, Ill., May 29, 2026 AbbVie announced that the European Commission (EC) has approved an expanded label for...
BeOne Sets New CLL Benchmark with 78-Month BRUKINSA Data at ASCO 2026
SAN CARLOS, Calif. | May 29, 2026 BeOne Medicines presented groundbreaking long-term data at the 2026 American Society of...
Nurix Therapeutics Showcases Bexobrutideg Data at EHA
BRISBANE, Calif., May 12, 2026 Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948)...
Advertisement
